search
Back to results

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (HF-REVERT)

Primary Purpose

Myocardial Infarction, Acute, Heart Failure, Left Sided

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
CDR132L
Placebo to CDR132L
Sponsored by
Cardior Pharmaceuticals GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myocardial Infarction, Acute

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria:

  1. Male or female patients, aged ≥ 30 to ≤ 80 years at the date of signing informed consent which is defined as the beginning of the Screening Period.
  2. Spontaneous acute mycardial infarction (AMI) (type I) based on the universal MI definition with randomization to occur no later than 14 days after index event diagnosis.
  3. Patient with a LVEF ≤ 45% as measured by ECHO after MI diagnosis (STEMI or NSTEMI).
  4. Patient with previous MI events in history can be included.
  5. Patient with body weight of ≤ 120 kg.
  6. N-terminal pro B-type natriuretic peptide level ≥ 125 pg/ml and < 8000 pg/ml at screening.
  7. Patient with STEMI/NSTEMI who underwent percutaneous coronary intervention for this event.

Exclusion Criteria:

  1. A woman of childbearing potential (WOCBP).
  2. Patient with HF of non-ischemic origin; e.g., myocarditis, alcoholic cardiomyopathy.
  3. Patient with New York Heart Association (NYHA) class IV at screening or randomization.
  4. Patient has any planned cardiac intervention (angiogram without angioplasty is acceptable) or any other planned surgery after the Screening Period.
  5. Patient has severe valvular heart disease.
  6. Patient has systolic BP < 90 mmHg or > 180 mmHg, diastolic BP < 50 mmHg or > 110 mmHg, and/or heart rate < 50 or > 100 beats/minute at screening or randomization.
  7. Patient with an estimated glomerular filtration rate < 30 mL/min/1.73 m2 or on dialysis.
  8. Patient with hepatic insufficiency classified as Child-Pugh B or C.
  9. Patient has medical history of disease(s) affecting the blood-brain-barrier, e.g., stroke within 6 months or multiple sclerosis.
  10. Patient has medical history of bleeding disorders or has thrombocytopenia (platelets < 100,000/μL).
  11. Patient has poorly controlled diabetes as determined by the Investigator.
  12. Patient has a history or presence of any of the following cardiac conditions: known structural cardiac abnormalities beyond HF, family history of long QT syndrome, cardiac syncope, or recurrent, idiopathic syncope.
  13. Any clinically significant abnormalities, at the discretion of the Investigator, in rhythm, conduction, or morphology of resting ECG that pose an additional safety risk to patients.
  14. Patient with active "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" infection confirmed as per the local testing guidelines at screening.
  15. Patient is not to be enrolled into the study if they received any prohibited therapy within 3 months of screening.

Sites / Locations

  • Fakultní nemocnice u sv. Anny v Brně
  • Institut klinicke a experimentalni medicinyRecruiting
  • Všeobecná fakultní nemocnice v PrazeRecruiting
  • St. Marien-Krankenhaus AhausRecruiting
  • Herzzentrum Dresden UniversitätsklinikRecruiting
  • Helios Klinikum Erfurt
  • Universitätsmedizin GreifswaldRecruiting
  • Universitätsmedizin GöttingenRecruiting
  • Universitätsklinik und Poliklinikfür Innere Medizin III
  • Medizinische Hochschule HannoverRecruiting
  • Universitätsklinikum Heidelberg
  • Universitätsklinikum Schleswig-HolsteinRecruiting
  • Klinikum Leverkusen GmbHRecruiting
  • Klinikum LudwigshafenRecruiting
  • Rheinland Klinikum Neuss GmbH - Lukaskrankenhaus
  • Klinik und Poliklinik für Innere Medizin II
  • SHG Kliniken VölklingenRecruiting
  • Universitätsklinikum WürzburgRecruiting
  • General University Hospital of Alexandroupolis
  • "Alexandra" General Hospital of Athens
  • "Ippokrateio" General Hospital of Athens
  • Diagnostic Therapeutic Center of Athens "HYGEIA"
  • General Hospital of Athens "Evaggelismos"
  • General Hospital of Athens "G. Gennimatas"
  • General Hospital of Nea Ionia Konstantopouleio - Patision
  • "Attikon" General University HospitalRecruiting
  • University General Hospital of Larisa
  • General University Hospital of Patras "Panagia i Voitheia"
  • Semmelweis University
  • Privát Kardiológiai Szakrendelö
  • BMKK Pándy Kálmán
  • BKS Research Ltd.
  • Somogy County Kaposi Mór Teaching Hospital
  • Medifarma-98 KFT
  • Kardiológiai belgyógyászati és diabetológiai magánrendelés Csongrad-Csanad Megies
  • Fejér County Hospital, Szent György Hospital
  • Jeroen Bosch Ziekenhuis (JBZ) (Hieronymus Bosch Hospital) - locatie Den BoschRecruiting
  • Deventer ZiekenhuisRecruiting
  • Slingeland ZiekenhuisRecruiting
  • Gelderse Vallei ZiekenhuisRecruiting
  • Medisch Centrum LeeuwardenRecruiting
  • St. Jansdal ZiekenhuisRecruiting
  • Erasmus University Medical CenterRecruiting
  • Ikazia ZiekenhuisRecruiting
  • D & A Research B.V.Recruiting
  • Gelre ZiekenhuizenRecruiting
  • Uniwersytecki Szpital Kliniczny w Bialymstoku (USK w Bialymstoku)Recruiting
  • Centrum Medyczne Lukamed Joanna Łuka
  • Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. Jana Pawla IIRecruiting
  • Medical University of Silesia
  • Specjalistyczna Poradnia Kardiologiczna i Nadcisnienia Tetniczego
  • Krakowski Szpital Specjalistyczny im. Jana Pawla IIRecruiting
  • Polsko Amerykanskie Kliniki SercaRecruiting
  • Szpital ZOZ w KlodzkuRecruiting
  • Gabinet Internistyczno-Kardiologiczny Jacek NowakRecruiting
  • One wojskowy Szpital Kliniczny w LublinieRecruiting
  • Medicome Sp. z o.o.Recruiting
  • Szpital Kliniczny Przemienienia PanskiegoRecruiting
  • Wojewódzki Szpital im. Sw. Ojca Pio w PrzemysluRecruiting
  • SP ZOZ Szpital Specjalistyczny w PulawachRecruiting
  • NZOZ Pro-Cordis Sopockie Centrum Bad. KardiologRecruiting
  • Wojewodzki Szpital ZespolonyRecruiting
  • Centralny Szpital Kliniczny MSW w Warszawie, ul.Recruiting
  • Warszawski Uniwersytet Medyczny
  • Spec.Szpital im.dr SokolowskiegoRecruiting
  • Investigational SiteRecruiting
  • NZOZ SALUS JZ PerugaRecruiting
  • Hospital Universitari Germans Trias i PujolRecruiting
  • Hospital de la Santa Creu I Sant PauRecruiting
  • Hospital Universitario San CecilioRecruiting
  • Hospital Universitario La PazRecruiting
  • Hospital Universitario Virgen de la ArrixacaRecruiting
  • Hospital Clinico Universitario Virgen de la VictoriaRecruiting
  • Hospital Universitario de SabadellRecruiting
  • Hospital Universitario Virgen MacarenaRecruiting
  • Hospital Clinico Universitario de ValenciaRecruiting
  • Complejo Hospitalario Universitario de VigoRecruiting
  • Bradford Royal InfirmaryRecruiting
  • Queen Elizabeth University HospitalRecruiting
  • Wycombe HospitalRecruiting
  • Richmond Pharmacology LimitedRecruiting
  • South Tees Hospital NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

CDR132L 5 mg

CDR132L 10 mg

Placebo

Arm Description

CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57

CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57

Placebo intravenous in single dose on Day 1, Day 29 and Day 57

Outcomes

Primary Outcome Measures

Echocardiography (ECHO)
Percent change from baseline (screening to occur at least 3 days after MI diagnosis as measured by ECHO [central laboratory]) in Left Ventricular End-Systolic Volume (LVESVI) at Month 6.

Secondary Outcome Measures

Full Information

First Posted
April 20, 2022
Last Updated
October 2, 2023
Sponsor
Cardior Pharmaceuticals GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT05350969
Brief Title
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
Acronym
HF-REVERT
Official Title
Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 27, 2022 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
November 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cardior Pharmaceuticals GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (to occur at least 3 days after MI diagnosis), a 6-month double-blind period, and a 6-month extension period with the End of Study (EOS) Visit at Day 360/Month 12. Two dosages of CDR132L will be tested against placebo on their effects on patients, who just had a heart attack in addition to standard care. The aim of the study is to show that CDR132L is safe and effective to improve heart failure in such patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction, Acute, Heart Failure, Left Sided

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Pharmacy staff is unblinded. They will hand-over prepared investigational medicinal product (IMP) in light-protected syringe.
Allocation
Randomized
Enrollment
280 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CDR132L 5 mg
Arm Type
Experimental
Arm Description
CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
Arm Title
CDR132L 10 mg
Arm Type
Experimental
Arm Description
CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo intravenous in single dose on Day 1, Day 29 and Day 57
Intervention Type
Drug
Intervention Name(s)
CDR132L
Intervention Description
CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
Intervention Type
Drug
Intervention Name(s)
Placebo to CDR132L
Intervention Description
Placebo to CDR132L
Primary Outcome Measure Information:
Title
Echocardiography (ECHO)
Description
Percent change from baseline (screening to occur at least 3 days after MI diagnosis as measured by ECHO [central laboratory]) in Left Ventricular End-Systolic Volume (LVESVI) at Month 6.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Male or female patients, aged ≥ 30 to ≤ 80 years at the date of signing informed consent which is defined as the beginning of the Screening Period. Spontaneous acute mycardial infarction (AMI) (type I) based on the universal MI definition with randomization to occur no later than 14 days after index event diagnosis. Patient with a LVEF ≤ 45% as measured by ECHO after MI diagnosis (STEMI or NSTEMI). Patient with previous MI events in history can be included. Patient with body weight of ≤ 120 kg. N-terminal pro B-type natriuretic peptide level ≥ 125 pg/ml and < 8000 pg/ml at screening. Patient with STEMI/NSTEMI who underwent percutaneous coronary intervention for this event. Exclusion Criteria: A woman of childbearing potential (WOCBP). Patient with HF of non-ischemic origin; e.g., myocarditis, alcoholic cardiomyopathy. Patient with New York Heart Association (NYHA) class IV at screening or randomization. Patient has any planned cardiac intervention (angiogram without angioplasty is acceptable) or any other planned surgery after the Screening Period. Patient has severe valvular heart disease. Patient has systolic BP < 90 mmHg or > 180 mmHg, diastolic BP < 50 mmHg or > 110 mmHg, and/or heart rate < 50 or > 100 beats/minute at screening or randomization. Patient with an estimated glomerular filtration rate < 30 mL/min/1.73 m2 or on dialysis. Patient with hepatic insufficiency classified as Child-Pugh B or C. Patient has medical history of disease(s) affecting the blood-brain-barrier, e.g., stroke within 6 months or multiple sclerosis. Patient has medical history of bleeding disorders or has thrombocytopenia (platelets < 100,000/μL). Patient has poorly controlled diabetes as determined by the Investigator. Patient has a history or presence of any of the following cardiac conditions: known structural cardiac abnormalities beyond HF, family history of long QT syndrome, cardiac syncope, or recurrent, idiopathic syncope. Any clinically significant abnormalities, at the discretion of the Investigator, in rhythm, conduction, or morphology of resting ECG that pose an additional safety risk to patients. Patient with active "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" infection confirmed as per the local testing guidelines at screening. Patient is not to be enrolled into the study if they received any prohibited therapy within 3 months of screening.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cardior Clinical Team
Phone
+49511338599
Ext
30
Email
clinical@cardior.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Johann Bauersachs, Prof. Dr.
Organizational Affiliation
Hannover Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fakultní nemocnice u sv. Anny v Brně
City
Brno
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Name
Institut klinicke a experimentalni mediciny
City
Praha
Country
Czechia
Individual Site Status
Recruiting
Facility Name
Všeobecná fakultní nemocnice v Praze
City
Praha
Country
Czechia
Individual Site Status
Recruiting
Facility Name
St. Marien-Krankenhaus Ahaus
City
Ahaus
Country
Germany
Individual Site Status
Recruiting
Facility Name
Herzzentrum Dresden Universitätsklinik
City
Dresden
Country
Germany
Individual Site Status
Recruiting
Facility Name
Helios Klinikum Erfurt
City
Erfurt
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Universitätsmedizin Greifswald
City
Greifswald
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsmedizin Göttingen
City
Göttingen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinik und Poliklinikfür Innere Medizin III
City
Halle
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Medizinische Hochschule Hannover
City
Hannover
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Heidelberg
City
Heidelberg
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Universitätsklinikum Schleswig-Holstein
City
Kiel
Country
Germany
Individual Site Status
Recruiting
Facility Name
Klinikum Leverkusen GmbH
City
Leverkusen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Klinikum Ludwigshafen
City
Ludwigshafen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Rheinland Klinikum Neuss GmbH - Lukaskrankenhaus
City
Neuss
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Klinik und Poliklinik für Innere Medizin II
City
Regensburg
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
SHG Kliniken Völklingen
City
Volklingen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Würzburg
City
Würzburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
General University Hospital of Alexandroupolis
City
Alexandroupolis
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
"Alexandra" General Hospital of Athens
City
Athens
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
"Ippokrateio" General Hospital of Athens
City
Athens
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Diagnostic Therapeutic Center of Athens "HYGEIA"
City
Athens
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
General Hospital of Athens "Evaggelismos"
City
Athens
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
General Hospital of Athens "G. Gennimatas"
City
Athens
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
General Hospital of Nea Ionia Konstantopouleio - Patision
City
Athens
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
"Attikon" General University Hospital
City
Athen
Country
Greece
Individual Site Status
Recruiting
Facility Name
University General Hospital of Larisa
City
Larissa
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
General University Hospital of Patras "Panagia i Voitheia"
City
Patra
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Semmelweis University
City
Budapest
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Privát Kardiológiai Szakrendelö
City
Békéscsaba
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
BMKK Pándy Kálmán
City
Gyula
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
BKS Research Ltd.
City
Hatvan
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Somogy County Kaposi Mór Teaching Hospital
City
Kaposvár
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Medifarma-98 KFT
City
Nyíregyháza
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Kardiológiai belgyógyászati és diabetológiai magánrendelés Csongrad-Csanad Megies
City
Szentes
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Fejér County Hospital, Szent György Hospital
City
Székesfehérvár
Country
Hungary
Individual Site Status
Not yet recruiting
Facility Name
Jeroen Bosch Ziekenhuis (JBZ) (Hieronymus Bosch Hospital) - locatie Den Bosch
City
's-Hertogenbosch
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Deventer Ziekenhuis
City
Deventer
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Slingeland Ziekenhuis
City
Doetinchem
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Gelderse Vallei Ziekenhuis
City
Ede
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Medisch Centrum Leeuwarden
City
Leeuwarden
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
St. Jansdal Ziekenhuis
City
Lelystad
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Erasmus University Medical Center
City
Rotterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Ikazia Ziekenhuis
City
Rotterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
D & A Research B.V.
City
Sneek
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Gelre Ziekenhuizen
City
Zutphen
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Uniwersytecki Szpital Kliniczny w Bialymstoku (USK w Bialymstoku)
City
Białystok
Country
Poland
Individual Site Status
Recruiting
Facility Name
Centrum Medyczne Lukamed Joanna Łuka
City
Chojnice
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. Jana Pawla II
City
Grodzisk Mazowiecki
Country
Poland
Individual Site Status
Recruiting
Facility Name
Medical University of Silesia
City
Katowice
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Specjalistyczna Poradnia Kardiologiczna i Nadcisnienia Tetniczego
City
Kielce
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Krakowski Szpital Specjalistyczny im. Jana Pawla II
City
Kraków
Country
Poland
Individual Site Status
Recruiting
Facility Name
Polsko Amerykanskie Kliniki Serca
City
Kędzierzyn-Koźle
Country
Poland
Individual Site Status
Recruiting
Facility Name
Szpital ZOZ w Klodzku
City
Kłodzko
Country
Poland
Individual Site Status
Recruiting
Facility Name
Gabinet Internistyczno-Kardiologiczny Jacek Nowak
City
Libiąż
Country
Poland
Individual Site Status
Recruiting
Facility Name
One wojskowy Szpital Kliniczny w Lublinie
City
Lublin
Country
Poland
Individual Site Status
Recruiting
Facility Name
Medicome Sp. z o.o.
City
Oświęcim
Country
Poland
Individual Site Status
Recruiting
Facility Name
Szpital Kliniczny Przemienienia Panskiego
City
Poznań
Country
Poland
Individual Site Status
Recruiting
Facility Name
Wojewódzki Szpital im. Sw. Ojca Pio w Przemyslu
City
Przemyśl
Country
Poland
Individual Site Status
Recruiting
Facility Name
SP ZOZ Szpital Specjalistyczny w Pulawach
City
Puławy
Country
Poland
Individual Site Status
Recruiting
Facility Name
NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog
City
Sopot
Country
Poland
Individual Site Status
Recruiting
Facility Name
Wojewodzki Szpital Zespolony
City
Toruń
Country
Poland
Individual Site Status
Recruiting
Facility Name
Centralny Szpital Kliniczny MSW w Warszawie, ul.
City
Warsaw
Country
Poland
Individual Site Status
Recruiting
Facility Name
Warszawski Uniwersytet Medyczny
City
Warsaw
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Spec.Szpital im.dr Sokolowskiego
City
Wałbrzych
Country
Poland
Individual Site Status
Recruiting
Facility Name
Investigational Site
City
Wrocław
Country
Poland
Individual Site Status
Recruiting
Facility Name
NZOZ SALUS JZ Peruga
City
Łódź
Country
Poland
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Germans Trias i Pujol
City
Badalona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital de la Santa Creu I Sant Pau
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario San Cecilio
City
Granada
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario La Paz
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen de la Arrixaca
City
Murcia
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario Virgen de la Victoria
City
Málaga
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario de Sabadell
City
Sabadell
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen Macarena
City
Sevilla
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario de Valencia
City
Valencia
Country
Spain
Individual Site Status
Recruiting
Facility Name
Complejo Hospitalario Universitario de Vigo
City
Vigo
Country
Spain
Individual Site Status
Recruiting
Facility Name
Bradford Royal Infirmary
City
Bradford
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Queen Elizabeth University Hospital
City
Glasgow
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Wycombe Hospital
City
High Wycombe
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Richmond Pharmacology Limited
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
South Tees Hospital NHS Foundation Trust
City
Middlesbrough
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

We'll reach out to this number within 24 hrs